Wuhan Humanwell Goes To America With $550m Epic Buy
This article was originally published in PharmAsia News
Executive Summary
One stone, three birds is what Humanwell aims for when the aspiring Chinese specialty pharma gains an entry to the U.S. market via acquisition of Epic Pharma. As a company little known outside China making its first international move, it hopes to gain access to a large product portfolio, exposure to the world's largest pharma market and upgrading its own manufacturing quality.